Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tyrosinase/gp100 Peptide Vaccine +/- GM-CSF in Resected Stage II Melanoma
NCT00003274Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Mar 1998
- Primary completion
- Sep 2001
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of tyrosinase peptide, gp100 antigen in melanoma, sponsored by University of Southern California. Started Mar 1998; status: completed.
02
Drugs
tyrosinase peptidegp100 antigen
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00003274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003274.